A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca’s experimental drug camizestrant significantly reduced the risk of disease progression or death in patients with advanced hormone receptor-positive, HER2-negative breast cancer by 56%, when prescribed based on early blood test results rather than visible tumor growth, experts announced Sunday at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
The international trial marks a major shift in cancer treatment strategy by using liquid biopsy—a blood test that detects ESR1 gene mutations indicating early resistance to standard hormone therapies. Camizestrant, a selective estrogen receptor degrader (SERD), was shown to be effective in patients with early treatment resistance, even before tumors could be detected via imaging.
“This is going to be very impactful for our patients,” said Dr. Hope Rugo, head of breast medical oncology at City of Hope, California. “We’re staying ahead of the curve rather than reacting after the disease has already progressed,” added Dr. Eleonora Teplinsky, another ASCO expert.
The Phase 3 clinical trial involved 3,256 women, all previously treated with aromatase inhibitors and CDK4/6 inhibitors like Pfizer’s Ibrance or Novartis’ Kisqali. Among them, 315 women who developed ESR1 mutations were selected for a randomized trial. Those who switched to camizestrant plus CDK4/6 inhibitors experienced a median 16 months of progression-free survival compared to 9.2 months in the control group that continued standard therapy.
Camizestrant is not yet FDA-approved, but based on these findings, it may soon be adopted as part of a new treatment paradigm for early intervention in breast cancer progression.
AstraZeneca CEO Pascal Soriot acknowledged that integrating liquid biopsy into routine practice would initially be challenging but emphasized it as the future of cancer care.
In a separate announcement at the same ASCO meeting, another AstraZeneca drug, Imfinzi (durvalumab), showed promise in improving outcomes for early-stage stomach and esophageal cancer patients. When added to chemotherapy before and after surgery, Imfinzi reduced the risk of cancer recurrence, progression, or death by 29%.
Both sets of results were published in the New England Journal of Medicine and are expected to have lasting implications for the future of oncology.
The world’s space community is heading to Antalya for the 77th International Astronautical Congress (IAC), taking place from 5 to 9 Octo...
Iran says the Strait of Hormuz will remain closed until the United States meets seven conditions agreed under a June memorandum, as President...
U.S. President Donald Trump has appointed Director of National Intelligence Jay Clayton to lead the administration’s latest effort to shape p...
The co-pilot of Israel bound flydubai flight attempted to carry out a “terrorist attack” with an axe during the flight, the United Arab Emirates prosecutor general said on Saturday.
Hammam al-Hammami, the Flydubai co-pilot accused of stabbing the captain of an Israel-bound flight on Wednesday in a suspected terrorist attack, was banned from flying by Oman over concerns about his radical views, U.S. media reported on Friday, citing people familiar with the matter.
Two Iranian nationals have been charged in Britain with preparing a suspected terrorist attack targeting the Jewish community in northern England, police said on Friday (2 October).
A major bridge across the Dnipro river in Kyiv was hit in a Russian air attack on Saturday, the city's mayor, Vitali Klitschko said, as strikes on the capital's infrastructure continue.
Azerbaijan’s President Ilham Aliyev warned against interference from outside actors in remarks at the 8th Congress of the New Azerbaijan Party in Baku on Friday 2 October.
Health advice now reaches people through social media, fitness apps, wearable technology and AI. From detoxes and protein-focused diets to skincare and fitness trends, online wellness content is shaping everyday health choices while raising concerns about misinformation and potential risks.
Global cholera deaths reached their highest annual level in more than 20 years in 2025, despite a decline in reported cases, according to the World Health Organization (WHO).
Chinese researchers have developed the world’s smallest CT scanner, a portable device designed to produce images of tiny fossils and archaeological relics.
Here's your AnewZ Daily Brief for 17 September 2026. These are the top five stories making headlines in the field of health.
Doctors in St. Louis have successfully separated Ethiopian two-year-old twin girls who were born joined at the head after a months-long series of complex operations culminating in a nearly 25-hour final procedure, doctors said on Wednesday.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment